PZN-107 (brentuximab vedotin biosimilar) / Pharmasyntez - LARVOL DELTA

Russian drugmaker Pharmasyntez launches phase I study of Adcetris biosimilar PZN-107 (GxP News) - "The trial will involve 23 medical institutions and is designed to compare the pharmacokinetics, immunogenicity, safety and efficacy of the Russian copy with those of the original Adcetris....A total of 108 patients will take part, and the trial is expected to be completed by the end of 2028."

New P1 trial • Classical Hodgkin Lymphoma